

## HR 7223

Right Rebate Act of 2018

**Congress:** 115 (2017–2019, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Dec 6, 2018

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Dec 13, 2018)

**Official Text:** <https://www.congress.gov/bill/115th-congress/house-bill/7223>

### Sponsor

**Name:** Rep. Schrader, Kurt [D-OR-5]

**Party:** Democratic • **State:** OR • **Chamber:** House

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Welch, Peter [D-VT-At Large]	D · VT		Dec 6, 2018

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Dec 6, 2018
Ways and Means Committee	House	Referred to	Dec 13, 2018

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

Bill	Relationship	Last Action
115 HR 7217	Related bill	<b>Dec 12, 2018:</b> Received in the Senate.
115 S 3702	Identical bill	<b>Dec 4, 2018:</b> Read twice and referred to the Committee on Finance.

### Summary (as of Dec 6, 2018)

#### Right Rebate Act of 2018

This bill requires drug manufacturers with Medicaid rebate agreements for covered outpatient drugs to disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).

## Actions Timeline

---

- **Dec 13, 2018:** Referred to the Subcommittee on Health.
- **Dec 6, 2018:** Introduced in House
- **Dec 6, 2018:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.